Research Analysts Issue Forecasts for Alkermes plc’s Q3 2025 Earnings (NASDAQ:ALKS)

Alkermes plc (NASDAQ:ALKS) – Equities researchers at Zacks Research upped their Q3 2025 earnings per share estimates for Alkermes in a report released on Wednesday, April 10th. Zacks Research analyst R. Department now forecasts that the company will post earnings of $0.52 per share for the quarter, up from their previous estimate of $0.43. The consensus estimate for Alkermes’ current full-year earnings is $2.23 per share.

Several other equities analysts have also recently commented on the stock. Robert W. Baird started coverage on shares of Alkermes in a report on Tuesday, March 19th. They set an “outperform” rating and a $37.00 price target on the stock. Jefferies Financial Group boosted their target price on Alkermes from $42.00 to $50.00 and gave the company a “buy” rating in a research note on Tuesday. UBS Group downgraded Alkermes from a “neutral” rating to a “sell” rating and set a $25.00 price target for the company. in a research note on Tuesday, February 20th. StockNews.com cut Alkermes from a “strong-buy” rating to a “buy” rating in a research note on Friday, February 23rd. Finally, TheStreet raised shares of Alkermes from a “c+” rating to a “b” rating in a research report on Thursday, February 15th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $35.25.

Alkermes Stock Down 2.3 %

NASDAQ:ALKS opened at $24.42 on Friday. Alkermes has a 1-year low of $22.01 and a 1-year high of $33.71. The firm has a market capitalization of $4.13 billion, a price-to-earnings ratio of 11.80 and a beta of 0.55. The company has a current ratio of 2.86, a quick ratio of 2.50 and a debt-to-equity ratio of 0.24. The business’s fifty day moving average price is $28.13 and its 200 day moving average price is $27.16.

Alkermes (NASDAQ:ALKS) last issued its quarterly earnings results on Thursday, February 15th. The company reported $0.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.51 by ($0.29). Alkermes had a net margin of 21.39% and a return on equity of 16.10%. The firm had revenue of $377.50 million for the quarter, compared to analyst estimates of $362.78 million. During the same quarter last year, the business posted ($0.02) earnings per share. The firm’s revenue for the quarter was up 23.9% compared to the same quarter last year.

Institutional Trading of Alkermes

Hedge funds have recently bought and sold shares of the stock. Vanguard Personalized Indexing Management LLC lifted its position in shares of Alkermes by 6.1% in the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 7,830 shares of the company’s stock worth $219,000 after acquiring an additional 452 shares during the period. Victory Capital Management Inc. boosted its stake in Alkermes by 0.6% during the third quarter. Victory Capital Management Inc. now owns 76,043 shares of the company’s stock worth $2,130,000 after buying an additional 481 shares in the last quarter. Alliancebernstein L.P. increased its holdings in Alkermes by 0.3% in the 4th quarter. Alliancebernstein L.P. now owns 195,581 shares of the company’s stock valued at $5,111,000 after buying an additional 500 shares during the period. Alps Advisors Inc. raised its stake in shares of Alkermes by 0.4% in the 3rd quarter. Alps Advisors Inc. now owns 122,916 shares of the company’s stock valued at $3,443,000 after buying an additional 529 shares in the last quarter. Finally, Captrust Financial Advisors lifted its holdings in shares of Alkermes by 4.3% during the 4th quarter. Captrust Financial Advisors now owns 13,402 shares of the company’s stock worth $350,000 after acquiring an additional 555 shares during the period. 95.21% of the stock is owned by institutional investors.

Insider Activity at Alkermes

In other news, SVP Christian Todd Nichols sold 10,417 shares of Alkermes stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $28.10, for a total value of $292,717.70. Following the transaction, the senior vice president now directly owns 65,911 shares in the company, valued at $1,852,099.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 4.76% of the stock is currently owned by company insiders.

Alkermes declared that its Board of Directors has initiated a share buyback program on Thursday, February 15th that authorizes the company to repurchase $400.00 million in shares. This repurchase authorization authorizes the company to purchase up to 8.2% of its shares through open market purchases. Shares repurchase programs are often an indication that the company’s management believes its stock is undervalued.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.